Today: 9 June 2026
Why IREN stock is whipsawing today as bitcoin slips and tech rally cools
29 December 2025
1 min read

Why IREN stock is whipsawing today as bitcoin slips and tech rally cools

NEW YORK, December 29, 2025, 12:27 ET — Regular session

  • IREN was down about 0.5% after swinging between $38.55 and $42.25.
  • Bitcoin eased below $88,000, with U.S.-listed crypto-linked stocks broadly lower.
  • Investors are watching thin year-end trading, Fed minutes and weekly jobless claims.

IREN Ltd (IREN.O) shares swung sharply on Monday and were last down 0.5% at $40.08 in midday New York trading. The stock has ranged from $38.55 to $42.25 so far in the session.

The whipsaw highlights how tightly the Nasdaq-listed name trades with risk appetite in the final week of the year, when holiday-thinned volumes can amplify moves.

It also reflects IREN’s dual exposure to two volatile themes: bitcoin mining and the build-out of data centers for artificial intelligence workloads. That combination can make the stock sensitive to both crypto prices and shifts in investor positioning around high-growth tech.

Bitcoin was down about 0.4% at $87,482, after trading between $86,780 and $90,247 earlier on Monday.

Other U.S.-listed bitcoin miners were lower, with Marathon Digital down 1.3%, Riot Platforms off 1.7% and CleanSpark down 0.6%.

The broader market tone was also softer, with Wall Street’s main indexes under pressure as megacap tech shares pulled back from last week’s gains, Reuters reported. “This is not the beginning of the end of the tech dominance — it’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust. Reuters

IREN operates renewable-powered data centers in North America that are used for bitcoin mining as well as AI cloud services, according to a Reuters company profile.

The company has drawn attention in recent months as miners look to diversify revenue by selling computing capacity for AI, after shifting economics in the crypto-mining business.

In November, Microsoft signed a $9.7 billion, five-year contract with IREN that includes access to Nvidia chips and related equipment, Reuters reported at the time.

IREN has also tapped capital markets this month. The company said it closed a $2.3 billion convertible notes offering and repurchased existing convertible notes, and it also priced an ordinary share offering tied to that refinancing. Convertible notes are bonds that can be converted into stock under certain conditions, which can increase share count over time.

With no new company announcements on Monday, traders have been left to price IREN largely off crypto moves and the broader tech backdrop.

Later this week, investors will also be watching for the Federal Reserve’s latest meeting minutes and the weekly jobless claims report, while U.S. markets will be shut on Thursday for New Year’s Day, Reuters reported.

For IREN, the next scheduled company catalyst is likely earnings. Nasdaq estimates the company will report around Feb. 11, though the date is algorithm-based and can change.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

MongoDB stock slides as “MongoBleed” exploitation warning puts database security in focus
Next Story

MongoDB stock slides as “MongoBleed” exploitation warning puts database security in focus

Go toTop